ArticleFrontiers in cellular and infection microbiology2026
Construction of a linezolid-resistant strain of methicillin-susceptible
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The emergence of linezolid-resistant methicillin-susceptible Staphylococcus aureus (MSSA) is a growing clinical threat, but the underlying mechanisms are unclear. Here, we generated stable resistant derivatives and used a multi-omics strategy to investigate the transcriptional and metabolic regulation underlying linezolid resistance in MSSA. Methods: A clinical isolate of linezolid-susceptible Results: The successfully induced linezolid-resistant derivative (LZR) exhibited a 16-fold increase in minimum inhibitory concentration (MIC) against linezolid (32 μg/mL) compared with the parental strain (2 μg/mL), and this resistant phenotype remained stable after 50 serial passages in antibiotic-free medium. CCCP was observed to reduce the MIC of LZR in a concentration-dependent manner. Transcriptomic and metabolomic analyses revealed widespread transcriptional reprogramming and metabolic perturbations in the resistant strain. Differentially expressed genes were mainly enriched in pathways associated with oxidative phosphorylation, ribosome function, and glycerolipid metabolism, while differential metabolites were primarily involved in the biosynthesis of secondary metabolites and amino acid metabolism. Integrated analysis identified key co-enriched pathways with distinct regulatory patterns, which collectively remodeled bacterial material and energy metabolism and were closely associated with the emergence of linezolid resistance. Conclusion: A stable linezolid-resistant MSSA strain was developed in this work, revealing an intricate network of regulatory interactions that drive resistance at both the transcriptional and metabolic levels. These findings provide an experimental foundation and theoretical basis for further understanding the mechanisms of linezolid resistance in MSSA and for developing strategies to combat resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.